Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

ViiV seeks FDA approval for two-drug HIV-1 regimen

Jennie Walters
October 26, 2018 6:50 PM UTC

ViiV Healthcare Ltd. (Brentford, U.K.) said it submitted an NDA to FDA for its single-tablet, two-drug regimen of dolutegravir and lamivudine to treat HIV-1 infection. The company used a Priority Review voucher to speed up the review.

A ViiV spokesperson told BioCentury the company used the tropical disease Priority Review voucher that GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) received this year when FDA approved malaria drug Krintafel tafenoquine...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Viiv Healthcare Ltd.